Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet
I'm PortAI, I can summarize articles.
Shares of Soleno Therapeutics (SLNO) fell 7% after Scorpion Capital disclosed a short position, highlighting risks linked to its drug Vykat XR for Prader-Willi syndrome. The report raised concerns about potential pre-diabetes/diabetes, pulmonary edema, and other health issues. Despite this, retail investors remain optimistic about the stock's future.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments